Stefano Forli

Dr. Stefano Forli


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2021 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
JEJerome Eberhardt
Jerome Eberhardt
DSDiogo Santos-Martins
Diogo Santos-Martins
ATAndreas F. Tillack
Andreas F. Tillack
SFStefano Forli
Stefano Forli
1

14 April 2016 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
SFStefano Forli
Stefano Forli
RHRuth Huey
Ruth Huey
MPMichael E Pique
Michael E Pique
MSMichel F Sanner
Michel F Sanner
DGDavid S Goodsell
David S Goodsell
AOArthur J Olson
Arthur J Olson

15 June 2016 in Nature
Verified
Journal Article
Open access
PDF file
KBKeriann M. Backus
Keriann M. Backus
BCBruno E. Correia
Bruno E. Correia
KLKenneth M. Lum
Kenneth M. Lum
SFStefano Forli
Stefano Forli
BHBenjamin D. Horning
Benjamin D. Horning
BCBenjamin F. Cravatt
Benjamin F. Cravatt
Small molecules are powerful tools for investigating protein function, and can serve as leads for new therapeutics, but most human proteins lack known small-molecule ligands; here, a quantitative analysis of cysteine-reactive small-molecule fragments screened against thousands of proteins is reported. Fragment-based ligand discovery (FBLD) is a powerful tool for the discovery of small-molecule probes and drugs for proteins, but the approach has been limited to screening only the small number of proteins that can be purified in large quantities. Benjamin Cravatt and colleagues have developed a novel method for performing FBLD directly in native proteomes and cells, and they use it in a quantitative analysis of cysteine-reactive small-molecule fragments screened against thousands of proteins. Covalent ligands were identified for more than 700 cysteines in both druggable proteins and proteins deficient in chemical probes, including transcription factors, adaptor/scaffolding proteins and uncharacterized proteins. Small molecules are powerful tools for investigating protein function and can serve as leads for new therapeutics. Most human proteins, however, lack small-molecule ligands, and entire protein classes are considered ‘undruggable’1,2. Fragment-based ligand discovery can identify small-molecule probes for proteins that have proven difficult to target using high-throughput screening of complex compound libraries1,3. Although reversibly binding ligands are commonly pursued, covalent fragments provide an alternative route to small-molecule probes4,5,6,7,8,9,10, including those that can access regions of proteins that are difficult to target through binding affinity alone5,10,11. Here we report a quantitative analysis of cysteine-reactive small-molecule fragments screened against thousands of proteins in human proteomes and cells. Covalent ligands were identified for >700 cysteines found in both druggable proteins and proteins deficient in chemical probes, including transcription factors, adaptor/scaffolding proteins, and uncharacterized proteins. Among the atypical ligand–protein interactions discovered were compounds that react preferentially with pro- (inactive) caspases. We used these ligands to distinguish extrinsic apoptosis pathways in human cell lines versus primary human T cells, showing that the former is largely mediated by caspase-8 while the latter depends on both caspase-8 and -10. Fragment-based covalent ligand discovery provides a greatly expanded portrait of the ligandable proteome and furnishes compounds that can illuminate protein functions in native biological systems.

31 July 2017 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
SHStephan M. Hacker
Stephan M. Hacker
KBKeriann M. Backus
Keriann M. Backus
MLMichael R. Lazear
Michael R. Lazear
SFStefano Forli
Stefano Forli
BCBruno E. Correia
Bruno E. Correia
BCBenjamin F. Cravatt
Benjamin F. Cravatt

6 January 2021 in Journal of Chemical Theory and Computation
Verified
Journal Article
Closed access
DSDiogo Santos-Martins
Diogo Santos-Martins
LSLeonardo Solis-Vasquez
Leonardo Solis-Vasquez
ATAndreas F Tillack
Andreas F Tillack
MSMichel F Sanner
Michel F Sanner
AKAndreas Koch
Andreas Koch
SFStefano Forli
Stefano Forli

29 July 2020 in Cell
Verified
Journal Article
Closed access
EVEkaterina Vinogradova
Ekaterina Vinogradova
XZXiaoyu Zhang
Xiaoyu Zhang
DRDavid Remillard
David Remillard
DLDaniel C. Lazar
Daniel C. Lazar
RSRadu M. Suciu
Radu M. Suciu
BCBenjamin F. Cravatt
Benjamin F. Cravatt